BGB-11417 (MCL): A trial testing the treatment BGB-11417 in patients with relapsed or refractory mantle cell lymphoma
A phase 2 trial examining BGB-11417 monotherapy in patients with relapsed or refractory mantle cell lymphoma (MCL).
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05471843
Trial aim and background
The aim of this trial is to examine the medication BGB-11417 in monotherapy in patients with relapsed or refractory MCL.
The trial consists of two parts:
Part 1: determines the safety of BGB-11417, potential side effects, the maximum tolerated dose and the recommended dose.
Part 2: evaluates how well BGB-11417 works at the recommended dose
Who can enter
Adults with relapsed or refractory MCL who have had previous systemic treatment may be eligible to apply.
Locations
Recruitment is taking place in the following UK locations:
- Churchill Hospital Oxford University NHS Trust, Headington
- University College Hospital, London
- Clatterbridge Cancer Centre, Wirral
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05471843
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.